Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Anesthetics, Inhalation --- Anesthetics, Intravenous --- Neuromuscular Nondepolarizing Agents --- Neuromuscular Blockade --- Synaptic Transmission --- physiology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.

Medicine --- bladder cancer --- robotic-assisted --- open --- radical cystectomy --- survival --- propensity score --- age --- urothelial carcinoma --- outcome --- anesthesia recovery periods --- cognitive impairment --- gamma-cyclodextrins --- neuromuscular blockade --- robotic radical cystectomy --- glycogen --- clear-cell adenocarcinoma --- urinary bladder --- SEER program database --- female --- intracorporeal neobladder --- outcomes --- robotic --- sex-sparing --- methylation --- biomarkers --- FOXA1 --- GATA3 --- KRT20 --- molecular markers --- mRNA --- muscle-invasive bladder cancer --- PCR --- human epidermal growth factor receptor 2 --- indoleamine 2,3-dioxygenase --- programmed death ligand-1 --- immunotherapy --- nodal disease --- pN1 --- neoadjuvant --- adjuvant --- chemotherapy --- bladder cancer --- robotic-assisted --- open --- radical cystectomy --- survival --- propensity score --- age --- urothelial carcinoma --- outcome --- anesthesia recovery periods --- cognitive impairment --- gamma-cyclodextrins --- neuromuscular blockade --- robotic radical cystectomy --- glycogen --- clear-cell adenocarcinoma --- urinary bladder --- SEER program database --- female --- intracorporeal neobladder --- outcomes --- robotic --- sex-sparing --- methylation --- biomarkers --- FOXA1 --- GATA3 --- KRT20 --- molecular markers --- mRNA --- muscle-invasive bladder cancer --- PCR --- human epidermal growth factor receptor 2 --- indoleamine 2,3-dioxygenase --- programmed death ligand-1 --- immunotherapy --- nodal disease --- pN1 --- neoadjuvant --- adjuvant --- chemotherapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.

bladder cancer --- robotic-assisted --- open --- radical cystectomy --- survival --- propensity score --- age --- urothelial carcinoma --- outcome --- anesthesia recovery periods --- cognitive impairment --- gamma-cyclodextrins --- neuromuscular blockade --- robotic radical cystectomy --- glycogen --- clear-cell adenocarcinoma --- urinary bladder --- SEER program database --- female --- intracorporeal neobladder --- outcomes --- robotic --- sex-sparing --- methylation --- biomarkers --- FOXA1 --- GATA3 --- KRT20 --- molecular markers --- mRNA --- muscle-invasive bladder cancer --- PCR --- human epidermal growth factor receptor 2 --- indoleamine 2,3-dioxygenase --- programmed death ligand-1 --- immunotherapy --- nodal disease --- pN1 --- neoadjuvant --- adjuvant --- chemotherapy --- n/a